Kroger Specialty Pharmacy Recalls Letrozole 2.5 mg Tablets Due to Processing Controls
Kroger Specialty Pharmacy is recalling Letrozole 2.5 mg tablets dispensed between December 2017 and February 2018 due to a lack of processing controls.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 2/5 (Moderate).
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, and the source text does not report any illnesses, injuries, or deaths, fitting the criteria for a moderate severity score.
Plain-English summary
Kroger Specialty Pharmacy, Inc. is recalling Letrozole 2.5 mg tablets (NDC 51991-0759-33) with a 30-day supply. The recall is being conducted due to a lack of processing controls.
The affected products were dispensed between December 1, 2017, and February 12, 2018. The recall covers all lots remaining within their expiration date that were dispensed during this period. The products were distributed in Mississippi, Louisiana, Arkansas, Illinois, and Florida.
Consumers who have these products should stop using them and contact their healthcare provider or pharmacist for further instructions.
The recalled product
- Product
- Letrozole 2.5 mg tab NDC 51991-0759-33 30 days supply
- Manufacturer
- Kroger Specialty Pharmacy, Inc.
- Category
- Drug — Prescription Medication
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All lots remaining within expiry dispensed 12/01/2017 through 02/12/2018
Distribution
Part of a larger recall action
This product is one of 67 recalled by Kroger Specialty Pharmacy, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 67 products in this recall →Related recalls
Same manufacturer · Kroger Specialty Pharmacy, Inc.
See all →- HighKroger Recalls Botox Due to Lack of Processing Controls
FDA (Drugs) · 2018-05-16
- HighKroger Recalls Capecitabine Tablets Due to Lack of Processing Controls
FDA (Drugs) · 2018-05-16
- ModerateKroger Specialty Pharmacy Recalls Cimzia 200 mg/mL PFS Kits
FDA (Drugs) · 2018-05-16
- HighKroger Recalls Lupron Depot Due to Lack of Processing Controls
FDA (Drugs) · 2018-05-16
- ModerateKroger Specialty Pharmacy Recalls Cyclophosphamide Capsules Due to Processing Controls
FDA (Drugs) · 2018-05-16
Same hazard · processing controls
See all →- HighCompounded tirzepatide 8.8 mg vials recalled over lack of processing controls
FDA (Drugs) · 2025-08-13
- HighCompounded tirzepatide 11.24 mg vials recalled over lack of processing controls
FDA (Drugs) · 2025-08-13
- HighCompounded semaglutide 0.22 mg vials recalled over lack of processing controls
FDA (Drugs) · 2025-08-13
- HighCompounded semaglutide 0.44 mg vials recalled over lack of processing controls
FDA (Drugs) · 2025-08-13
- HighCompounded tirzepatide 4.4 mg vials recalled over lack of processing controls
FDA (Drugs) · 2025-08-13
Similar recalls
- SevereLetrozole Tablets Recalled for Potential Mislabeling as Metoprolol Tartrate
FDA (Drugs) · 2014-01-22
- Severe
- ModerateReliable Drug Recalls Fluconazole Products Due to Processing Control Issues
FDA (Drugs) · 2016-07-13
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- ModerateMasterPharm Recalls Progesterone Troches Due to Processing Control Deficiencies
FDA (Drugs) · 2020-08-05
- SevereRedline Pharmacy Recalls Morphine Sulfate Due to Processing Controls
FDA (Drugs) · 2020-03-18